Phaseline

Targets › GGTA1

GGTA1 (Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase): drug programs, companies and trials

4 programs from 3 companies in 4 trials: 3 Phase 1, 1 Phase 2; Genitourinary, Oncology; next expected readout Jan 2028.

Open in Phaseline: the race on GGTA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Prescient TherapeuticsPTX-100
Peptidomimetic inhibitor of GGTase 1
GGTA1Phase 2CTCLJan 2028
Xeno Holdings (US), LLC dba ChoironeXChoironeX GalKO Porcine Thymokidney
Genetically modified porcine thymokidney with knockout of alpha-gal epitope (GalKO) for xe
GGTA1Phase 1End Stage Renal DiseaseJun 2028
United Therapeutics10 GE Xenokidney
Porcine-derived kidney with intentional genomic alterations (knockout of GGTA1, CMAH, BHMT
GGTA1, CMAH, BHMT, PERVPhase 1ESRD (End-Stage Renal Disease)Oct 2028
United TherapeuticsGGTA1 KO Thymokidney
Porcine kidney with GGTA1 gene knockout (xenotransplant) combined with thymic tissue autog
GGTA1Phase 1ESRD (End-Stage Renal Disease)Nov 2029

Conditions

ESRD (End-Stage Renal Disease) (2) End Stage Renal Disease (1) CTCL (1)

Modalities

protein or peptide (3), small molecule (1)

Companies

United Therapeutics (2) Xeno Holdings (US), LLC dba ChoironeX (1) Prescient Therapeutics (1)

Related targets

CMAH (1) BHMT (1) PERV (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.